1. Home
  2. |Insights
  3. |2018 Antitrust M&A Year in Review

2018 Antitrust M&A Year in Review

Client Alert | 1 min read | 03.01.19

Crowell & Moring LLP is pleased to release its "2018 Antitrust M&A Year in Review." Following a year of significant and industry-transforming transactions, this publication provides insight and analysis into developments and trends in global antitrust enforcement of mergers and acquisitions. We examine how changes, such as the first full-year of Trump administration appointments at the Antitrust Division and the seating of five new FTC Commissioners, have impacted the U.S. antitrust agencies’ enforcement priorities and policies. We also look at merger control in the EU, which saw a record-breaking number of filings in 2018.

The report spotlights areas that were particularly noteworthy in 2018, including telecom and media, health care, and policy changes regarding vertical mergers. We also take a look at the implications of China’s regulatory activity on merger control and its role in global merger review.

Given the likelihood that recent antitrust merger enforcement developments foreshadow what to expect in the coming year, the 2018 Antitrust M&A Year in Review provides insight into trends that will be highly relevant going forward. We hope that you will find this report useful and welcome your feedback.

Click here to access the report PDF.

 

Contacts

Insights

Client Alert | 6 min read | 04.29.26

CMS Seeks to Expand Interoperability Requirements to Drug Pre-Authorization (FAQ)

On April 10, 2026, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule (2026 CMS Interoperability Standards and Prior Authorization for Drugs, or CMS-0062-P) outlining the agency’s plans to impose new interoperability requirements on payors participating in certain Medicare and Medicaid programs. As described by the agency in a recent press release, the proposed rule “builds on” prior rulemaking by clarifying and enhancing interoperability requirements for payors’ prior authorization processes, specifically those associated with coverage requests for pharmaceutical therapies....

View All Insights